Terms: = Ovarian cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Diagnosis
15 results:
1. Mass Spectrometry-Based Proteomics of Epithelial ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
2. Nivolumab, nivolumab-ipilimumab, and vegfr-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
[TBL] [Abstract] [Full Text] [Related]
3. Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
Sköld C; Koliadi A; Enblad G; Stålberg K; Glimelius I
Int J Cancer; 2022 Mar; 150(5):773-781. PubMed ID: 34648676
[TBL] [Abstract] [Full Text] [Related]
4. Gene expression in the Angiopoietin/TIE axis is altered in peripheral tissue of ovarian cancer patients: A prospective observational study.
Kinnen A; Klaschik S; Neumann C; Egger EK; Mustea A; Soehle M; Frede S; Velten M; Coburn M; Hilbert T
Life Sci; 2021 Jun; 274():119345. PubMed ID: 33713666
[TBL] [Abstract] [Full Text] [Related]
5. Impact of Multiparametric MRI (mMRI) on the Therapeutic Management of Adnexal Masses Detected with Transvaginal Ultrasound (TVUS): An Interdisciplinary Management Approach.
Dirrichs T; Bauerschlag D; Maass N; Kuhl CK; Schrading S
Acad Radiol; 2022 Feb; 29(2):183-197. PubMed ID: 33293256
[TBL] [Abstract] [Full Text] [Related]
6. MicroRNA‑195 suppresses cell proliferation, migration and invasion in epithelial ovarian carcinoma via inhibition of the CDC42/CCND1 pathway.
Hao X; Jia Q; Yuan J; Shi X; Guo H; Gao J; Guo Y
Int J Mol Med; 2020 Nov; 46(5):1862-1872. PubMed ID: 32901852
[TBL] [Abstract] [Full Text] [Related]
7. Identification of high-affinity vegfr3-binding peptides through a phage-displayed random peptide library.
Shi LF; Wu Y; Li CY
J Gynecol Oncol; 2015 Oct; 26(4):327-35. PubMed ID: 26197772
[TBL] [Abstract] [Full Text] [Related]
8. Serum angiopoietin-2 and soluble vegfr-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
Sallinen H; Heikura T; Koponen J; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
BMC Cancer; 2014 Sep; 14():696. PubMed ID: 25245329
[TBL] [Abstract] [Full Text] [Related]
9. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract] [Full Text] [Related]
10. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
Wimberger P; Chebouti I; Kasimir-Bauer S; Lachmann R; Kuhlisch E; Kimmig R; Süleyman E; Kuhlmann JD
Gynecol Oncol; 2014 Jun; 133(3):467-72. PubMed ID: 24713547
[TBL] [Abstract] [Full Text] [Related]
11. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Vecchione A; Belletti B; Lovat F; Volinia S; Chiappetta G; Giglio S; Sonego M; Cirombella R; Onesti EC; Pellegrini P; Califano D; Pignata S; Losito S; Canzonieri V; Sorio R; Alder H; Wernicke D; Stoppacciaro A; Baldassarre G; Croce CM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9845-50. PubMed ID: 23697367
[TBL] [Abstract] [Full Text] [Related]
12. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
[TBL] [Abstract] [Full Text] [Related]
13. The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia.
Zhu P; Ning Y; Yao L; Chen M; Xu C
J Exp Clin Cancer Res; 2010 Sep; 29(1):124. PubMed ID: 20831794
[TBL] [Abstract] [Full Text] [Related]
14. Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation.
Paulsen T; Ree AH; Kaern J; Kjaerheim K; Bassarova A; Berner A; Haldorsen T; Tropé C; Nesland JM
Eur J Gynaecol Oncol; 2007; 28(5):356-63. PubMed ID: 17966213
[TBL] [Abstract] [Full Text] [Related]
15. Expression of vascular endothelial growth factor and its receptors flt and kdr in ovarian carcinoma.
Boocock CA; Charnock-Jones DS; Sharkey AM; McLaren J; Barker PJ; Wright KA; Twentyman PR; Smith SK
J Natl Cancer Inst; 1995 Apr; 87(7):506-16. PubMed ID: 7707437
[TBL] [Abstract] [Full Text] [Related]
